← Back to Home

Restoring Both Metabolic and Repair Signals to Aging Bones: Dual-Layer Nanovesicles Promote Bone Regeneration in Rats

A research team packaged a metabolic cofactor and stem cell-derived nanovesicles into a single dual-layer carrier, improving bone defect repair in aged female rats. The findings offer a new design for cell-free regenerative therapy, but extensive validation remains necessary before human application.

By SURL BioNews

Aging not only makes bone-forming cells less responsive but also causes the area around a wound to remain in an inflammatory state unfavorable to repair for prolonged periods. A study published in *Nature Communications* sought to address both obstacles simultaneously by using dual-compartment nanovesicles to coordinate metabolic, immune, and stem cell states, promoting bone defect repair in aged female rats.

The research team first used a multi-omics approach to analyze regenerating bone tissue and found that S-adenosylmethionine (SAM) was markedly reduced in the aging environment. SAM is a metabolic cofactor required for various methylation reactions. Its deficiency may disrupt epigenetic regulation, making it more difficult for cells to maintain normal function and providing a mechanistic rationale for the team’s decision to supplement SAM.

To deliver both types of signals into cells, the researchers designed a concentric dual-compartment system called a “nanoconcentrisome.” Its core consists of mesenchymal stem cell-derived nanovesicles, while the outer layer is a cell membrane-fusible liposome loaded with SAM. The study indicates that this structure can deliver its contents into the cytoplasm and reduce the degradation of cargo after it enters lysosomes. A related Chinese patent describes it as a carrier approximately 120 nanometers in size, with the two layers linked through click chemistry.

Cell experiments showed that the system does more than transport materials. It can reduce inflammatory activation in macrophages, enhance their ability to clear apoptotic cells, and alter their metabolic state. In senescent stem cells, the researchers observed improvements in epigenetic integrity, mitochondrial function, and osteogenic differentiation. In other words, the therapeutic concept is to reorganize the repair environment while restoring the cells responsible for carrying out regeneration.

In a bone defect model using aged female rats, animals treated with the dual-compartment vesicles showed better tissue regeneration and defect repair. This distinguishes the approach from the direct transplantation of living stem cells: delivering signals through cell-derived vesicles could theoretically avoid some of the storage, survival, and behavioral instability issues associated with living-cell products. Zhejiang University has obtained a Chinese patent covering applications in cellular reprogramming, regulation of the inflammatory microenvironment, tissue regeneration, and age-related bone diseases. The paper also discloses that two of its authors are inventors of the patent.

However, these remain early preclinical findings. The study validated bone repair only in aged female rats, so it cannot yet be assumed that males, other age groups, or human patients would experience the same effects. The in vivo distribution, long-term safety, immune response, dosage, and duration of nanovesicles, as well as whether batch consistency can be maintained during large-scale manufacturing, all require further clarification. The version currently published by the journal has also not yet completed editorial processing. Formal clinical translation will still require additional animal studies and human trials.

References

  1. Nature Communications
  2. Google Patents